ARID1A and ovarian carcinoma: Given the strong negative association of mutation status and detectable protein expression [16] we considered this assay as a surrogate mutation test useful in segregating endometriosis associated ovarian cancer from other subtypes, most notably high-grade serous, as ARID1A mutations appear to be exceedingly rare in this subtype [16], [45].